CCBs and antihypertensive medicines that target the renin-angiotensin system were selected for this review as a result of their very wide use, since they are first line antihypertensive drug classes [17, 18], and possess potential evidence of association with PCa [9]. This evidence concerns the gene REN and posterior cortical atrophy.